Chronic dosing with mirtazapine does not produce sedation in rats

Objective: Sedation/somnolence are major side effects of pharmacotherapies for depression, and negatively affect long-term treatment compliance in depressed patients. Use of mirtazapine (MIR), an atypical antidepressant approved for the treatment of moderate to severe depression with comorbid anxiety disorders, is associated with significant sedation/somnolence, especially in short-term therapy. Nonetheless, studies with human subjects suggest that MIR-induced sedation is transient, especially when high and repeated doses are used. The purpose of this study was to explore the effects of acute and chronic administration of different doses of MIR on sedation in the rat. Methods: Assessment of sedation was carried out behaviorally using the rotarod, spontaneous locomotor activity, and fixed-bar tests. Results: A 15-mg/kg dose of MIR induced sedative effects for up to 60 minutes, whereas 30 mg/kg or more produced sedation within minutes and only in the first few days of administration. Conclusion: These results suggest that 30 mg/kg is a safe, well-tolerated dose of MIR which generates only temporary sedative effects.

Eficacia clínica de un antidepresivo de la tercera generación (Trazodone) en pacientes con cuadros depresivos / Clinic efficiency of one antidepressive of the third with depressive states

En este ensayo clínico se estudió la eficacia clínica del Trazodone, antidepresivo, no tricíclico, no IMAO, derivado triazolopiridina. Hemos estudiado 67 pacientes deprimidos, con edades comprendidas entre 18 a 70 años, con un seguimiento clínico y psiquiátrico periódico a lo largo de 42 días. La dosis inicial utilizada debe ser de 50 mg/día, aumentándose hasta 150 mg/día según evolución del paciente. Los resultados apreciados de manera global demuestran que el Trazodone es un antidepresivo eficaz en las diferentes formas clínicas de la depresión